Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease.

BACKGROUND & AIMS Azathioprine (AZA) and 6-mercaptopurine (6-MP) are used in pediatric patients with ulcerative colitis and Crohn's disease to reduce disease activity, maintain remission, prevent relapse, and lower corticosteroid dosage, but their long-term side effects remain to be studied. The aim of this study was to analyze the safety of AZA and 6-MP and steroid reduction in this age group. METHODS The investigators' database identified 118 patients who received either drug; 23 were excluded (single visit, noncompliance, or therapy < 1 week), leaving 95 patients, with a mean (+/-SD) age of 14.2 +/- 4.4 years. Medical files were reviewed for adverse side effects: fever, pancreatitis, infections, gastrointestinal intolerance, aminotransferase level increase, leukopenia, and thrombocytopenia. Prednisone doses before and after immunomodulatory therapy were compared. RESULTS AZA or 6-MP was tolerated in 51 of 95 patients (54%) without adverse reaction; 27 of 95 (28%) experienced side effects that responded to dose reduction (23 patients) or spontaneously (4 patients), most commonly increased aminotransferase level (13.7%). Cessation of therapy was needed in 17 of 95 patients (18%), including recurrent fever (4), pancreatitis (4), gastrointestinal intolerance (4), and recurrent infections (3). Mean prednisone dose decreased from 24.3 to 8.6 mg/day. CONCLUSIONS AZA and 6-MP were well tolerated in 82% of patients; of these, prednisone reduction occurred in 87%. However, 18% required discontinuation because of hypersensitivity or infectious side effects.

[1]  D. Franchimont,et al.  Crohn's Disease , 1976, The Lancet.

[2]  B. Pasternack,et al.  Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. , 1980, The New England journal of medicine.

[3]  J. Markowitz,et al.  Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. , 1990, Gastroenterology.

[4]  G PLACITELLI,et al.  [Ulcerative colitis]. , 1958, La Riforma medica.

[5]  M. Kamm,et al.  Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. , 1993, Gut.

[6]  R. Ricketts.  Immunosuppressive therapy in pediatric inflammatory bowel disease: Results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition , 1993 .

[7]  D. Lowe,et al.  Disseminated varicella complicating ulcerative colitis. , 1978, JAMA.

[8]  C. FordAlexander,et al.  ULCERATIVE colitis. , 1997, Journal of the American Medical Association.

[9]  R. Modigliani,et al.  Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine , 1996, The Lancet.

[10]  Comprehensive textbook of oncology , 1986 .

[11]  Y. Théorêt,et al.  6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. , 1996, Gut.

[12]  D. Sachar,et al.  Extraintestinal cancers in inflammatory bowel disease , 1985, Cancer.

[13]  W. Walker.  Pediatric Gastrointestinal Disease: Pathophysiology, Diagnosis, Management , 1990 .

[14]  G. Mullin,et al.  Lymphoma in inflammatory bowel disease , 2010, Cancer.

[15]  J. Markowitz,et al.  Immunology of inflammatory bowel disease: summary of the proceedings of the Subcommittee on Immunosuppressive Use in IBD. , 1991, Journal of pediatric gastroenterology and nutrition.

[16]  I. Leodolter.  [Crohn's disease]. , 1967, Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete.

[17]  J. Karlberg,et al.  Longitudinal Growth in Children and Adolescents with Inflammatory Bowel Disease , 1994, Journal of pediatric gastroenterology and nutrition.

[18]  B. Korelitz,et al.  The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. , 1994, The American journal of gastroenterology.

[19]  J. Markowitz,et al.  Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum. , 1993, The American journal of gastroenterology.

[20]  B. Kirschner.  Growth and Development in Chronic Inflammatory Bowel Disease , 1990, Acta paediatrica Scandinavica. Supplement.

[21]  S. Meltzer,et al.  6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. , 1989, Annals of internal medicine.

[22]  J. Markowitz,et al.  Growth failure in pediatric inflammatory bowel disease. , 1993, Journal of pediatric gastroenterology and nutrition.

[23]  S. Shevell,et al.  Ocular toxicity of prednisone in pediatric patients with inflammatory bowel disease. , 1992, Lens and eye toxicity research.

[24]  G. Hommel,et al.  Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. , 1993, Gastroenterology.

[25]  H. Winter,et al.  Azathioprine in the treatment of children with inflammatory bowel disease. , 1990, The Journal of pediatrics.

[26]  M. Ament.  Ulcerative Colitis and Crohn’s Disease in Children , 1982 .

[27]  P. Rutgeerts,et al.  Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. , 1997, Gastroenterology.

[28]  S. Meltzer,et al.  Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. , 1986, Gastroenterology.

[29]  J. Soulé,et al.  Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease. , 1994, The New England journal of medicine.

[30]  M. steckman.  Treatment of Crohn's disease with 6-mercaptopurine: what effects on fertility? , 1980, The New England journal of medicine.

[31]  W. Sandborn.  6-MP metabolite levels: a potential guide to Crohn's disease therapy. , 1997, Gastroenterology.

[32]  S. Kraker,et al.  Overwhelming varicella pneumonia in a patient with Crohn's disease treated with 6-mercaptopurine. , 1995, Journal of pediatric gastroenterology and nutrition.

[33]  J. Hyams,et al.  Extraintestinal manifestations of inflammatory bowel disease in children. , 1994, Journal of pediatric gastroenterology and nutrition.

[34]  R. Grand,et al.  Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. , 1996, Journal of pediatric gastroenterology and nutrition.

[35]  M. Kamm,et al.  Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease , 1994, The Lancet.

[36]  B. Lashner.  Risk factors for small bowel cancer in Crohn's disease , 1992, Digestive diseases and sciences.

[37]  A. Axon,et al.  Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. , 1992, BMJ.

[38]  W. Sandborn.  A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. , 1996, The American journal of gastroenterology.